A single institution experience with palbociclib toxicity requiring dose modifications
Sign Up to like & getrecommendations! Published in 2017 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-017-4606-9
Abstract: PurposeSince the widespread implementation of adding palbociclib to endocrine therapy in clinical practice, myelosuppression is becoming increasingly recognized as a toxicity that may lead to dose modification. We aimed to characterize toxicities observed with palbociclib… read more here.
Keywords: palbociclib; palbociclib dose; dose modification; toxicity ... See more keywords